Evidence map›Paper›PMID 37111308›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

A Novel Hydroxyapatite/Vitamin B

Amany Belal, Rehab Mahmoud, Eman E Mohamed, Ahmed Farghali, Fatma I Abo El-Ela, Amr Gamal, Fatma Mohamed Halfaya, Esraa Khaled, Abdelbasset A Farahat, Ahmed H E Hassan and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 5 countries.

Amany BelalDepartment of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Taif 21944, Saudi Arabia.
Rehab MahmoudDepartment of Chemistry, Faculty of Science, Beni-Suef University, Beni-Suef 62511, Egypt.
Eman E MohamedMolecular Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University, Beni-Suef 62511, Egypt.
Ahmed FarghaliMaterials Science and Nanotechnology Department, Faculty of Postgraduate Studies for Advanced Sciences, Beni-Suef University, Beni-Suef 62511, Egypt.
Fatma I Abo El-ElaDepartment of Pharmacology, Faculty of Veterinary Medicine, Beni-Suef University, Beni-Suef 62511, Egypt.ORCID 0000-0002-2165-9432
Amr GamalDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62511, Egypt.
Fatma Mohamed HalfayaDepartment of Surgery, Anesthesiology and Radiology, Faculty of Veterinary Medicine, Beni-Suef University, Beni-Suef 62511, Egypt.
Esraa KhaledMaterials Science and Nanotechnology Department, Faculty of Postgraduate Studies for Advanced Sciences, Beni-Suef University, Beni-Suef 62511, Egypt.
Abdelbasset A FarahatMaster of Pharmaceutical Sciences Program, California Northstate University, 9700 W Taron Dr., Elk Grove, CA 95757, USA.ORCID 0000-0003-0664-5670
Ahmed H E HassanDepartment of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0002-1048-6281
Mohammed M GhoneimDepartment of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Ad Diriyah 13713, Saudi Arabia.ORCID 0000-0002-9179-4373
Mohamed TahaMaterials Science and Nanotechnology Department, Faculty of Postgraduate Studies for Advanced Sciences, Beni-Suef University, Beni-Suef 62511, Egypt.
Mohamed Y ZakyMolecular Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University, Beni-Suef 62511, Egypt.ORCID 0000-0002-2387-593X
Beni-Suef University · EGMansoura University · EGAlfaisal University · SALinköping University · SETaif University · SA

Funding

King Salman Center for Disability Research KSRG-2022-047
6 · The paper itself

Abstract

The usage of nanomaterials for rheumatoid arthritis (RA) treatment can improve bioavailability and enable selective targeting. The current study prepares and evaluates the in vivo biological effects of a novel hydroxyapatite/vitamin B

Indexed as

anti-arthriticanti-inflammatoryantioxidantbone damagebone disability researchnano-HAP/Vit B12rheumatoid arthritis

Identifiers

PMID37111308
PMCPMC10143295
OpenAlexW4362669286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.